ROSE for Improved Molecular Marker Testing Via EBUS

Enrolling by invitation · Not applicable

Conditions studied: Non-small Cell Lung Cancer (NSCLC)

In brief

This research study is being done to compare two ways to conduct bronchoscopic biopsy of lymph nodes and other structures in the chest (i.e. the presence or absence of an on-site cytotechnologist performing a limited microscopic evaluation to provide non-binding feedback on specimen adequacy in real time during the procedure).

Key facts

Study ID

NCT04945317

Run by

Johns Hopkins University

People needed

349

Starts

2021-05-14

Expected to finish

2026-12-31

Last updated by the study team

2025-12-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Inpatients or outpatients >18 years old
• Capable of informed consent
• Known or suspected non-small cell lung cancer (NSCLC)
• Referred to the interventional pulmonary team at Johns Hopkins Hospital (JHH), Johns Hopkins Bayview Medical Center (JHBMC), or other participating sites for tissue sampling of a hilar/mediastinal lymph node or another lesion accessible by convex-probe (CP) EBUS

You may not qualify if…

• Refuse participation
• Standard contraindications to EBUS and bronchoscopy in general: bleeding disorders, antiplatelet or anticoagulant usage, high fraction of inspired oxygen (FiO2) requirement, and clinical instability
• Pregnant women
• Cytotechnologist not available at the time of screening, enrollment, or randomization

Where it is running

• Northwestern Medicine — Chicago, Illinois, United States
• Johns Hopkins Bayview Medical Center — Baltimore, Maryland, United States
• Johns Hopkins Hospital — Baltimore, Maryland, United States
• The Medical University of South Carolina (MUSC) — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.